

# WILSON SONSINI

## Martin J. Waters

PARTNER

Corporate  
San Diego

mwaters@wsgr.com  
858-350-2308



## FOCUS AREAS

Biotech  
Capital Markets  
Corporate  
Corporate Governance  
Corporate Life Sciences  
Emerging Companies and  
Venture Capital  
Life Sciences  
Mergers & Acquisitions

## HIGHLIGHTS

- **A Proven Company Builder**  
With more than 30 years of experience providing corporate and securities counsel, Marty has been instrumental in starting, building, and shepherding numerous emerging growth companies through IPOs or strategic partnerships.
- **Southern California Focus**  
A founding partner of the San Diego office and Southern California corporate practice, Marty leads the firm's efforts in representing public and private growth companies in San Diego, Orange County, and Los Angeles.
- **A Recognized Practitioner**  
Ranked Band 1 by *Chambers USA* for his corporate work in Southern California, Marty has been recognized as a leading corporate attorney in multiple editions of *Chambers USA*, as well as *San Diego Metropolitan Magazine*, *IPO Journal*, and *LMG Life Sciences*.

## EXPERIENCE

Martin (Marty) Waters is a corporate and securities partner in the San Diego office. He is a founding partner of the firm's San Diego office and Southern California corporate practice. He was a partner in the Palo Alto office until opening the San Diego office in 2004. He is a current member of the firm's board of directors.

Marty is a proven company builder with more than 30 years of experience providing corporate and securities counsel to high growth private and public companies. He has been instrumental in starting, building, and shepherding numerous emerging growth life sciences and technology companies through IPOs or strategic partnerships. Marty also represents several public companies in a general counsel capacity, as well as investment banks and placement agents in PIPEs and public offerings. Marty has counseled issuers and underwriters in more than 50 offerings.

Recognized in *Chambers USA: America's Leading Lawyers for Business* since 2011, Marty is "highly respected for the superlative quality of the corporate counsel he offers corporate clients." Sources describe him as a "a trusted partner" who "consistently delivers great advice" with a "specialty in managing complex and difficult stalemates."

## CREDENTIALS

### Education

- J.D., Georgetown University Law Center, 1991
- B.A., Georgetown University, 1988

*Cum Laude*

### Associations and Memberships

- Member, Board of Directors, Wilson Sonsini Goodrich & Rosati
- Former Member, Board of Directors, COMMNEXUS
- Former Member, Board of Directors, CONNECT
- Co-founder, PEERs Network

### Honors

- Named among *San Diego Business Journal's* 2025 "Leaders of Influence in Life Sciences"
- Named among Southern California's top corporate attorneys in the 2011-2026 editions of *Chambers USA: America's Leading Lawyers for Business*, earning kudos for his representation of emerging growth companies and seen as "pragmatic, forward-thinking and thorough"
- Selected for inclusion in the 2023-2024 editions of *Best Lawyers in America*
- Recognized among San Diego's top corporate attorneys for 2011 and 2012 by *San Diego Metropolitan Magazine*
- Recognized as a "Life Science Star" in the finance and transactional section of *LMG Life Sciences* in 2012 and 2013
- Named to "Lawdragon 500 Leading Dealmakers"
- Named to "Lawdragon 500 New Stars, New Worlds"
- Ranked by the *IPO Journal* in the top 10 of the publication's "Top 100 Lawyers Acting as IPO Issuer's Counsel"

### Admissions

- State Bar of California
- State Bar of New York
- State Bar of Wyoming

## SELECT TRANSACTIONS

---

### Public Offerings

- Illumina IPO
- Immunity Bio (formerly Nantkwest IPO)
- Inogen IPO
- RXST IPO
- Lenz IPO
- Ventyx IPO

### Mergers & Acquisitions and Strategic Partnerships

- DTX Pharma sale to Novartis
- Vertos Medical sale to Stryker
- Technosylva strategic growth investment from TA Associates
- CoreValve sale to Medtronic
- Eyeonics sale to Bausch & Lomb

### Venture Financings

- Represented Concentric Analgesics in its \$76 million Series B
- Represented ABK Biomedical in its \$30 million Series B
- Represented Vertiflex in its \$40 million Series C